Evidence map›Paper›PMID 29486768›Full record

ArticleJournal of neuroinflammation2018

Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.

Hannah D Fulenwider, Britessia M Smith, Anna S Nichenko, Jessica M Carpenter, Sadie E Nennig, Kejun Cheng, Kenner C Rice, Jesse R Schank

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hannah D FulenwiderDepartment of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, 501 D.W. Brooks Drive, Athens, GA, 30602, USA.
Britessia M SmithDepartment of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, 501 D.W. Brooks Drive, Athens, GA, 30602, USA.
Anna S NichenkoDepartment of Kinesiology, University of Georgia, 115 Ramsey Center, 330 River Road, Athens, GA, 30602, USA.
Jessica M CarpenterDepartment of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, 501 D.W. Brooks Drive, Athens, GA, 30602, USA.
Sadie E NennigDepartment of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, 501 D.W. Brooks Drive, Athens, GA, 30602, USA.
Kejun ChengNIDA and NIAAA IRP, 9800 Medical Center Drive, Rm 228A MSC-3373, Bethesda, MD, 20892, USA.
Kenner C RiceNIDA and NIAAA IRP, 9800 Medical Center Drive, Rm 228A MSC-3373, Bethesda, MD, 20892, USA.
Jesse R SchankDepartment of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, 501 D.W. Brooks Drive, Athens, GA, 30602, USA. jschank@uga.edu.
University of Georgia · USCenter for Drug Evaluation and Research · USNational Institutes of Health · US

Funding

Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid ReceptorsZIADA000527 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2025
$23.2M
The Role of the Neurokinin-1 Receptor and NF kappa B in alcohol-induced behaviorR00AA021805 · NIAAA · UNIVERSITY OF GEORGIA · PI SCHANK, JESSE R · 2014 to 2016
$724k
National Institute on Alcohol Abuse and Alcoholism AA021805NIAAA NIH HHS R00 AA021805
6 · The paper itself

Abstract

backgroundSeveral psychiatric conditions are affected by neuroinflammation and neuroimmune activation. The transcription factor nuclear factor kappa light-chain-enhancer of activated B cells (NFkB) plays a major role in inflammation and innate immunity. The neurokinin-1 receptor (NK1R) is the primary endogenous target of the neuroactive peptide substance P, and some data suggests that NK1R stimulation may influence NFkB activity. Both NK1R and NFkB have been shown to play a functional role in complex behaviors including stress responsivity, depression, and addiction. In this study, we test whether NFkB activity in the brain (stimulated by lipopolysaccharide administration) is dependent upon the NK1R.

methodsAdult male Wistar rats were treated systemically with the NK1R antagonist L822429 followed by administration of systemic lipopolysaccharide (LPS, a strong activator of NFkB). Hippocampal extracts were used to assess expression of proinflammatory cytokines and NFkB-DNA-binding potential. For behavioral studies, rats were trained to consume 1% (w/v) sucrose solution in a continuous access two-bottle choice model. After establishment of baseline, animals were treated with L822429 and LPS and sucrose preference was measured 12 h post-treatment.

resultsSystemic LPS treatment causes a significant increase in proinflammatory cytokine expression and NFkB-DNA-binding activity within the hippocampus. These increases are attenuated by systemic pretreatment with the NK1R antagonist L822429. Systemic LPS treatment also led to the development of anhedonic-like behavior, evidenced by decreased sucrose intake in the sucrose preference test. This behavior was significantly attenuated by systemic pretreatment with the NK1R antagonist L822429.

conclusionsSystemic LPS treatment induced significant increases in NFkB activity, evidenced by increased NFkB-DNA binding and by increased proinflammatory cytokine expression in the hippocampus. LPS also induced anhedonic-like behavior. Both the molecular and behavioral effects of LPS treatment were significantly attenuated by systemic NK1R antagonism, suggesting that NK1R stimulation lies upstream of NFkB activation following systemic LPS administration and is at least in part responsible for NFkB activation.

Indexed as

AnhedoniaAnimalsHippocampusLipopolysaccharidesMaleNeurokinin-1 Receptor AntagonistsNF-kappa BPiperidinesRatsRats, WistarReceptors, Neurokinin-1LipopolysaccharidesN-((2-cyclopropoxy-5-(5-trifluomethyl)tetrazol-1-yl)benzyl)-2-phenylpiperidin-3-amineNeurokinin-1 Receptor AntagonistsNF-kappa BPiperidinesReceptors, Neurokinin-1AnhedoniaCytokinesDepressionInflammationLipopolysaccharideNeuroimmune systemNeurokinin-1 receptorNuclear factor kappa B

Identifiers

PMID29486768
PMCPMC6389133
OpenAlexW2797955714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.